Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis.
We describe two multiple sclerosis patients who displayed widespread urticaria due to intramuscular interferon beta-1a (INF-β-1a). Clinicians should be aware of this adverse event, since it may be severe and it may lead to the definitive interruption of treatment. Widespread urticaria complicating intramuscular INF-β-1a therapy in multiple sclerosis should be therefore added to the list of dermatological lesions associated with interferon therapy.
Guijarro
Cristina
C
Department of Neurology, University Hospital 12 de Octubre, Madrid, Spain.
Benito-León
Julián
J
Bermejo-Pareja
Félix
F
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D014581:Urticaria / Q000139:chemically induced*
D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a